Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
DNA · against 480 other Healthcare companies of similar size
Ranked #421 of 481 · scores higher than 11% of peers
Bars: peers in each 10-point band of the profitability score48 peers with a profitability score of 10–19, including DNA · Click a bar to see the companies
Mainly because of its return on invested capital and operating margin, which are weaker than most Healthcare peers.
| Metric | DNA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Return on invested capitalHigher is better · 455 reported | -72.0% | 3.2% | 8% | 33% | |
| Operating marginHigher is better · 449 reported | -231.1% | 5.5% | 8% | 33% | |
| Return on assetsHigher is better · 475 reported | 2.2% | 1.3% | 61% | 33% | |
| Return on equityHigher is better · 457 reported | -59.9% | 1.6% | 10% | Context only | |
| Gross marginHigher is better · 499 reported | 68.0% | 42.5% | 78% | Context only |
| Rank | Company | Market cap | Profitability | Overall |
|---|---|---|---|---|
| 1 | 97.3B INR (≈$1.2B) | 100 | 80 | |
| 2 | 595M USD | 99 | 97 | |
| 2 | 433M USD | 99 | 81 | |
| 2 | 578M USD | 99 | 73 | |
| 2 | 914M USD | 99 | 81 | |
| 417 | 424M USD | 15 | 45 | |
| 417 | 1.3B USD | 15 | 29 | |
| 420 | 684M USD | 14 | ||
| 421 | 968M USD | 13 | 37 | |
| 421 | 725M USD | 13 | 19 | |
| 421 | 1.4B USD | 13 | 38 | |
| 421 | 1.2B CHF (≈$1.3B) | 13 | 28 | |
| 421 | 1.4B USD | 13 | 39 | |
| 421 | 534M USD | 13 | 32 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score